Reply to Schoppman et al.

Endoscopy 2013; 45(02): 153
DOI: 10.1055/s-0032-1326102

Letters to the editor

C. P. J. Caygill

,

C. Royston

,

A. Charlett

,

C. M. Wall

,

P. A. C. Gatenby

,

J. R. Ramus

,

A. Watson

,

M. Winslet

,

K. D. Bardhan

References
1 Caygill CPJ, Royston C, Charlett A et al. Mortality in Barrett’s esophagus: three decades of experience at a single center. Endoscopy 2012; 44: 892-898
2 Spechler SJ. Barrett’s esophagus without dysplasia: wait or ablate?. Dig Dis Sci 2011; 56: 1926-1928
3 Sikkema M, Looman CWN, Steyerberg EW et al. Predictors for neoplastic progression in patients with Barrett’s esophagus: a prospective cohort study. Am J Gastroenterol 2011; 106: 1231-1238
4 Caygill CPJ, Royston C, Charlett A et al. Barrett’s, blood groups and progression to oesophageal cancer: is nitric oxide the link?. Eur J Gastroenterol Hepatol 2011; 23: 801-806
5 Bardhan KD, Strugala V, Dettmar PW. Reflux revisited: advancing the role of pepsin. Int J Otolaryngol 2012; 646901 Epub 2011 Nov 10